Drug targeting DP103 shows promise for triple negative breast cancer
Researchers at the National University of Singapore have identified that the drug RX-5902 can inhibit the DP103 gene, which drives tumor growth in triple-negative breast cancer. Lab models showed significant reduction in tumor size and cancer stem cell viability, offering a potential path for personalized treatment.
Why it matters
Triple-negative breast cancer is an aggressive subtype with few targeted therapies; this discovery could significantly improve survival rates for a high-risk patient population.
NUS Centre for Cancer Research assistant professor Alan Prem Kumar (centre, foreground) with researchers (background, from left) Cai Wanpei, Lam Hiu Yan and Xianning Lai.
PHOTO: NUS YONG LOO LIN SCHOOL OF MEDICINE
Listen Summarise NUS researchers found that the drug RX-5902 can turn off the master switch gene DP103, reducing tumour growth and cancer stem cell survival in aggressive triple-negative breast cancer. The drug showed a 40-60% reduction in cancer stem cell viability and around 90% tumour size reduction in lab models, extending survival and sparing healthy cells. DP103 may serve as a biomarker to identify patients who will benefit most from RX-5902, enabling personalised treatments and potential applications in other cancers driven by Wnt signalling. AI generated
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in